الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Our study aimed to study the effect of iron and ESA therapy on Erythroferrone level and its correlations with Iron parameters and response to therapy in End stage renal disease patients.
Observational prospective study was conducted on 40 patients with end stage renal disease (ESRD) (GFR < 15ml/min/1.73 mm3) with evidence of iron deficiency anemia who attended Ain Shams university Hospitals. patients subdivided into two subgroups “subgroup 1: treatment with iron and erythropoietin, subgroup 2 : treatment with iron” .
The patients mean age was 51.03±11.22 years with females/males ratio 1.5. Subgroup 1 mean age was 49.96±12.05 with female/male ratio 1.5, while subgroup 2 mean age was 54.11±8.15 with female/male ratio 1.4. While control group mean age was 50.78±11.71 years with female / male ratio 1 with no significant difference in age and sex between control and both patient groups.
Our study shows statistically significant increase in mean erythroferrone level post iron/EPO treatment (520.00±255.26 & 458.89±175.17 in subgroup 1 & 2 respectively) compared to baseline level (212.31±106.33 and 172.22±90.25 in subgroup 1 & 2 respectively) in subgroup 1 and subgroup 2 with (p value <0.001 HS, <0.004 S respectively in subgroup 1 & 2 respectively).
Also we demonstrate a highly statistically significant increase of post iron/ESA treatment hemoglobin level (p value <0.001) compared to baseline in subgroup 1 and subgroup 2 with p value <0.001 in both subgroups. Also a highly statistically significant increase in mean HCT level of post treatment with iron/EPO compared to baseline (p value <0.001), although there was no statistically difference in MCV and MCH levels.
We detected that ERFE level directly correlated to Hb level (p value<0.05) and iron level (p value<0.05) in all patients.
In our study we detected a significant increase in TSAT post-treatment in all patients comparing to baseline levels (p-value 0.001) and (p value <0.001 and 0.003 in subgroup 1 and subgroup 2 respectively).
Our study showed a significant decrease in TIBC level post-treatment in all patients comparing to baseline levels (p = 0.019).